Clostridium Difficile Infections Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: March 21, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 955.4 million |
|
Revenue Forecast in 2031 |
US$ 1,727.1 million |
|
CAGR |
6.8% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global Clostridium difficile infections treatment market was valued at US$ 955.4 million in 2022 and is expected to register a revenue CAGR of 6.8% to reach US$ 1,727.1 million by 2031.
Clostridium Difficile Infections Treatment Market Fundamentals
The most frequent cause of nosocomial infectious diarrhea is Clostridium difficile. Both inpatients and outpatients are becoming more likely to contract Clostridium difficile infection (CDI), and outbreaks brought on by a particularly aggressive strain of the bacteria are leading to more serious illness. The most frequent cause of nosocomial infectious diarrhea is now known to be Clostridium difficile. It causes more than 90% of cases of antibiotic-associated pseudomembranous colitis, up to 75% of cases of antibiotic-associated colitis, and up to 25% of cases of antibiotic-associated diarrhea. Moreover, individuals without the conventional risk factors for CDI, such as antibiotic usage, advanced age, and serious underlying disease, are developing the condition. A moderate, self-limiting diarrheal sickness to a fulminant, life-threatening colitis are on the clinical severity scale for CDI. The most popular laboratory technique for identifying Clostridium difficile toxins is an enzyme-linked immunosorbent test, which can provide a diagnosis within a few hours. The severity of the condition should be considered when selecting a treatment. Oral metronidazole is typically the preferred medication for mild to moderate CDI, but severe CDI is best treated with oral vancomycin. Prompt surgical intervention is crucial in patients with severe, complex CDI. For mild to moderate CDI, oral metronidazole is usually recommended. This advice for mild to moderate CDI is based on the substantial cost savings and equivalent efficacy compared with oral vancomycin. 79–81 Based on trials that revealed much higher cure rates than metronidazole in patients with severe CDI, oral vancomycin, is now the first-line treatment for these patients. Possible antibiotic treatments include bacitracin, rifampin, rifaximin, nitazoxanide, fusidic acid, and teicoplanin, in addition to vancomycin and metronidazole. The rates of symptomatic cure with bacitracin are comparable to those of vancomycin, while the rates of bacteriological cure are lower. Rifaximin, nitazoxanide, and fusidic acid appear to have the same effectiveness as metronidazole and vancomycin.
[68678]
Clostridium Difficile Infections Treatment Market Dynamics
The majority of long-term antibiotic use is connected to CDI. Increased antibiotic usage changes the colon’s bacterial composition and promotes Clostridium difficile growth. Antibiotics, such as cephalosporins, clindamycin, and quinolones, are more likely to cause CDI. Doctors prescribe antibiotics for a variety of reasons. Hence, some patients could anticipate receiving an antibiotic prescription and even request one from their physician. The prevalence of CDIs is rising due to the increased usage of these antibiotics, probably driving up demand for their treatments. Thus, the growing consumption of antibiotics is a key factor driving growth in the global market for treating CDIs. Additionally, increased medication research activities that will give clinicians more alternatives for alternative treatments are the key factor propelling the market revenue growth. As better treatment and prevention are anticipated to drive market revenue growth, developing new classes of non-antibiotic drugs and vaccines will open up many opportunities for market players while increasing the competitive pressure for innovative medicines.
Government authorities across many developed and developing countries are taking the necessary actions to educate the public about the availability of therapies for nosocomial illnesses that can be lethal. Governments are planning and launching many awareness campaigns, gatherings, and health insurance. With more initiatives and awareness campaigns, the market is projected to grow. Several commercial and governmental organizations and significant businesses are actively working to promote awareness of CDI by implementing various awareness campaigns or publishing recommendations for the illness, according to a Global Organization Providing C. difficile support, education, and advocacy C. diff. Survivors Network, November has been proclaimed C. difficile Awareness Month, and it is an exciting time for fundraising and gatherings for families, clinicians, and organizations. Governors in several states honor the effort by signing proclamations declaring November Clostridium difficile Awareness Month in their states.
However, few antibiotics are now available for treating CDI, hence many pharmaceutical companies are presently concentrating on creating non-antibiotic substitutes. Creating new medication classes will provide market participants with considerable potential for expansion, but it will also unavoidably necessitate substantial investments in the research and development of innovative treatments. The extremely high investment needs could be a hindrance to market revenue growth.
Clostridium Difficile Infections Treatment Market Ecosystem
The global Clostridium difficile infections treatment market is analyzed from three perspectives: drug, distribution channel, and region.
Clostridium Difficile Infections Treatment Market by Drug
[24567]
Based on the drug, the global Clostridium difficile infections treatment market is segmented into metronidazole, vancomycin, fidaxomicin, metronidazole, and probiotics.
The vancomycin segment accounted for the largest revenue share of the global Clostridium difficile infections treatment market in 2022. Regardless of the severity of the disease, vancomycin is currently the chosen first-line treatment for all CDI. The most often prescribed medications for CDI treatment are metronidazole and vancomycin. The three randomized controlled trials released thus far and the planned tolevamer trial use intermediate endpoints as opposed to the clinically important outcomes of complication or recurrence frequency. The primary benefit of vancomycin is its affordability. Vancomycin administered orally has a better pharmacokinetic profile, which is its main benefit. One potential downside of these medications is that they may encourage the colonization and infection of vancomycin-resistant enterococci.
Metronidazole is considered the second-line treatment for CDIs. Due to this medicine’s easy availability, the segment is growing with the fastest CAGR. Metronidazole hydrochloride has historically been considered first-line therapy for patients with mild to moderate CDI before the approval of vancomycin.
Clostridium Difficile Infections Treatment Market by Distribution Channel
Based on the distribution channel, the global Clostridium difficile infections treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment accounted for the largest revenue share of the global Clostridium difficile infections treatment market in 2022. Patients receiving medical care may get nosocomial infections or infections related to healthcare, such as CDIs. Both wealthy and poor nations around the world are affected by these illnesses. Nosocomial infections cause 7% of deaths in industrialized countries and 10% in developing nations. These infections, which occur while an individual is in the hospital, may result in a lengthier stay, a handicap, and a financial burden. Therefore, the prolonged stay in the hospital influences the patient to consider the hospital pharmacies as the most reliable option for buying medicines. Thus, hospital pharmacies play a significant role in improving treatments for the various issues associated with CDI. As a result, hospital pharmacies that provide direct treatment for CDI have seen a large increase in sales. Additionally, various government programs, including the subsidized medicine program, assist patients in purchasing pricey therapies for infectious ailments regardless of their financial circumstances. Due to rising prescription costs and the dearth of pharmaceuticals in retail pharmacies, people now prefer hospital pharmacies, which has significantly increased revenue.
Clostridium Difficile Infections Treatment Market by Region
Based on the region, the global Clostridium difficile infections treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global Clostridium difficile infections treatment market in 2022. The high prevalence of CDIs in North America is the main driving force behind the rapid increase in the market revenue share. Office of Disease Prevention and Health Promotion of the U.S. Department of Health and Human Services took the National Action Plan to Prevent Health Care-Associated Infections initiative to recognize healthcare-associated infections as an important public health and patient safety issue. A well-developed healthcare infrastructure, industry leaders, recently launched cutting-edge instruments, and payment coverage are all thought to be contributing to the region’s high demand for sophisticated healthcare services.
Due to a rise in awareness of gastric illness in the region, Europe is regarded as the second-largest market for CDI medications. Owing to the high frequency of diarrhea, growing adolescent population, and quickly expanding healthcare infrastructure in the region, Asia Pacific is anticipated to account for the greatest market revenue share for CDI medications over the coming years.
Clostridium Difficile Infections Treatment Market Competitive Landscape
The global market for treating Clostridium difficile infections is moderately competitive due to product launches, mergers, and acquisitions. The main development approaches that many organizations are targeting include the introduction of novel therapies, obtaining approval for those products, and participating in additional activities like awareness projects. Also, the market regarded alliances, purchases, and countless other forms of cooperation as superior growth strategies. These initiatives have increased the likelihood of profitable growth prospects due to the growing global demand for treating CDIs.
Notable market participants include:
Clostridium Difficile Infections Treatment Market Strategic Developments
Clostridium difficile (C. diff) is a type of bacteria that can cause colitis, a serious colon inflammation. To treat this infection, several antibiotics are used, such as vancomycin.
Increasing antibiotic resistance over conventional treatments necessitates new treatments for CDIs, fueling market revenue growth.
The lack of proper investment in research and development is the key factor restraining the growth of the global Clostridium difficile infections treatment market.
Key companies operating the global Clostridium difficile infections treatment market are Pfizer, Inc., Rebiotix, Inc., Romark L.C., Sanofi Pasteur SA, and Seres Therapeutics, Inc.
The global Clostridium difficile infections treatment market is expected to grow at a revenue CAGR of 6.8% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain